Molecular pathogenesis of human hepatocellular carcinoma, Nature Genetics, vol.31, issue.4, pp.339-385, 2002. ,
DOI : 10.1038/ng0802-339
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nature Genetics, vol.30, issue.5, pp.505-516, 2015. ,
DOI : 10.1371/journal.pone.0038686
URL : https://hal.archives-ouvertes.fr/inserm-01159736
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, Nature Genetics, vol.35, issue.12, pp.1267-73, 2014. ,
DOI : 10.1186/1471-2105-11-189
Functional and genetic deconstruction of the cellular origin in liver cancer, Nature Reviews Cancer, vol.15, issue.11, pp.653-67, 2015. ,
DOI : 10.1053/j.gastro.2013.10.013
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Molecular classification of hepatocellular carcinoma anno 2011, Cancer Res Eur J Cancer, vol.6947, issue.712, pp.7385-921789, 2009. ,
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nature Protocols, vol.99, issue.1, pp.44-57, 2009. ,
DOI : 10.1038/nprot.2008.211
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties, Oncogene, vol.372, issue.40, pp.3526-3562, 2009. ,
DOI : 10.1038/onc.2009.211
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease, Science, vol.313, issue.5795, pp.1929-1964, 2006. ,
DOI : 10.1126/science.1132939
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Regulation of cancer cell metabolism, Nature Reviews Cancer, vol.118, issue.2, pp.85-95, 2011. ,
DOI : 10.1038/nrc2981
Transforming growth factor-?? gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer, Hepatology, vol.24, issue.2, pp.2059-67, 2008. ,
DOI : 10.1002/hep.22283
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction, Cell, vol.136, issue.5, pp.823-860, 2009. ,
DOI : 10.1016/j.cell.2009.02.024
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nature Medicine, vol.149, issue.4, pp.410-416, 2006. ,
DOI : 10.1111/j.1349-7006.2003.tb01366.x
EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features, Gastroenterology, vol.136, issue.3, pp.1012-1036, 2009. ,
DOI : 10.1053/j.gastro.2008.12.004
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma, Gastroenterology, vol.149, issue.5, pp.1226-1265, 2015. ,
DOI : 10.1053/j.gastro.2015.05.061
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, New England Journal of Medicine, vol.348, issue.26, pp.2609-2626, 2003. ,
DOI : 10.1056/NEJMoa030288
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation, Journal of Hepatology, vol.52, issue.1, pp.88-95, 2010. ,
DOI : 10.1016/j.jhep.2009.10.011
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nature Reviews Cancer, vol.105, issue.1, pp.38-51, 2006. ,
DOI : 10.1038/nrc1779
Resveratrol and cellular mechanisms of cancer prevention, Annals of the New York Academy of Sciences, vol.73, issue.1 ,
DOI : 10.1111/j.1749-6632.2010.05870.x
Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.3, issue.37, pp.5541-52, 2007. ,
DOI : 10.1016/j.bbrc.2005.12.144
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression Inflammatory cytokines promote the retrodifferentiation of tumor-derived hepatocyte-like cells to progenitor cells, J Leukoc Biol Hepatology, vol.9160, issue.296, pp.321-312077, 2012. ,
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group, Journal of Clinical Oncology, vol.30, issue.27, pp.3361-3368, 2012. ,
DOI : 10.1200/JCO.2011.41.2395
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design, Clinical Cancer Research, vol.20, issue.8, pp.2072-2081, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-0547
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, Journal of Hepatology, vol.64, issue.5 ,
DOI : 10.1016/j.jhep.2016.01.012